The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study

Table 1

Distribution of the studied groups according to comorbidities.

	Presence of comorbidity				value
	Group I (with comorbidity) (74)		Group II (without comorbidity) (74)
	N	(%)	N	(%)
Symptoms
History of fever	55	74.3	21	28.4	<0.001
Conjunctival congestion	20	27.0	2	2.7	<0.001
Nasal congestion	24	32.4	16	21.6	0.14
Headache	58	78.4	31	41.9	<0.001
Cough	58	78.4	46	62.2	0.031
Sore throat	58	78.4	43	58.1	0.008
Sputum production	4	5.4	1	1.4	0.37
Fatigue	58	78.4	30	40.5	<0.001
Shortness of breath	64	86.5	11	14.9	<0.001
Nausea	22	29.7	4	5.4	<0.001
Vomiting	12	16.2	2	2.7	0.005
Diarrhea	4	5.4	1	1.4	0.37
Myalgia	28	37.8	4	5.4	<0.001
Cyanosis	4	5.4	0	0.0	0.12
Complications
Pneumonia	20	27.0	5	6.8	0.001
ARDS	28	37.8	0	0.0	<0.001
Outcome of hospitalization
Died	28	37.8	0	0.0	<0.001
Survived	46	62.2	74	100
Before any adjustment	N = (80)		N = (105)
Gender
Male	46	57.5	48	45.7	0.03
Female	34	42.5	67	54.3
Age
<18 y	0	0.0	12	11.4	0.002
≥18 y	80	100	93	88.6
Outcome of hospitalization
Died	28	35.0	0	0.0	<0.001
Survived	52	65.0	105	100
After adjustment with gender^	N = (76)		N = (81)
Gender
Male	44	57.9	48	59.3	0.86
Female	32	42.1	33	40.7
Age
<18 y	0	0.0	12	14.8	<0.001
≥18 y	76	100	69	85.2
Outcome of hospitalization
Died	28	36.8	0	0.0	<0.001
Survived	48	63.2	81	100
After gender and age adjustment^	N = (74)		N = (74)
Gender
Male	42	56.8	43	58.1	0.87
Female	32	43.2	31	41.9
Age
<18 y	0	0.0	3	4.1	0.08
≥18 y	74	100	71	95.9
Outcome of hospitalization
Died	28	37.8	0	0.0	<0.001
Survived	46	62.2	74	100

Significant at . Significant at . ^Adjustment using propensity score matching. CT: computerized topography.